News

Tuesday, 18. May 2021 | Filed under Company News

Company News: BellaSeno Wins Prestigious German Innovation Award 2021

– Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies

BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business – Medical Technologies. BellaSeno has been chosen among about 700 applicants from 30 countries, covering both bluechip as well as innovative start-up companies.

Read more…

Tuesday, 18. May 2021 | Filed under Company News

Company News: MerLion Pharmaceuticals Completes Growth Financing Round

– Proceeds will be used to facilitate MerLion`s production and market launch of XtoroTM

MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors.

The funds raised will primarily be used to finance the production and market launch of MerLion’s US FDA and Health Canada approved drug XtoroTM, an otic suspension containing finafloxacin for treatment of ear infections.

Read more…

Monday, 12. April 2021 | Filed under Company News

Company News: ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases

– Company forms international consortium with ProteoGenix SAS and Amsterdam UMC

ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that it has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).

Read more…